News & Publications

News

SEP 13, 2022

hC Bioscience Appoints Brad Margus to its Board of Directors

hC Bioscience, Inc., a company developing first-
in-class tRNA-based therapeutics targeting protein dysfunction in genetically defined

diseases, today announced the appointment of industry veteran Brad Margus to its
board of directors.
“We are excited to welcome Brad to the company during this pivotal time of growth,”
said Leslie Williams, co-founder, director and chief executive officer of hC Bioscience.

SEP 6, 2022

HC Bioscience Expands Leadership And Research & Development Team

 

hC Bioscience, Inc., a biotech company developing first-in-class tRNA-based therapeutics targeting protein dysfunction in genetically defined diseases and cancer, today announced it has expanded its executive and research & development teams with the additions of Yosef Landesman, Ph.D., as chief scientific officer and Gautam Goel, Ph.D., as chief data science officer.

FEB 24, 2022

tRNA therapeutics burst onto startup scene

Nature Biotechnology (2022)

Companies advance tRNA therapeutics to overcome mutant stoppages in protein synthesis shared by thousands of genetic diseases and cancers…and the field continues to expand with the arrival of hC Bioscience, a startup that emerged from stealth mode in late February with $24 million and a plan to fight cancer and rare diseases with tRNA…

3d render biological cell virus

FEB 23, 2022

hC Bioscience Announces $24 Million Series A Financing to Develop Innovative Pipeline of Protein-Editing Therapies

hC Bioscience, Inc., a drug discovery and development company focused on first-in-class tRNA-based therapeutics targeting protein dysfunction, has closed a Series A financing of $24 million led by a strong syndicate of investors, including ARCH Venture Partners, Takeda Ventures and 8VC…

Featured

Sep 19, 2021

tRNA therapies could help restore proteins lost in translation

A new class of therapies based on transfer RNA could treat forms of cystic fibrosis, muscular dystrophy, genetic epilepsies, and more

Publications

FEB 10, 2021

Therapeutic promise of engineered nonsense suppressor tRNAs

Nonsense mutations change an amino acid codon to a premature termination codon (PTC) generally through a single-nucleotide substitution…

FEB 18, 2019

Engineered transfer RNAs for suppression of premature termination codons

The appearance of the premature translation termination codons (PTCs)…

A new class of therapies based on transfer RNA could treat forms of cystic fibrosis, muscular dystrophy, genetic epilepsies, and more

tRNA therapies could help restore proteins lost in translation

Sept 13, 2022

hC Bioscience Appoints Brad Margus to its Board of Directors

hC Bioscience, Inc., a company developing first-in-class tRNA-based therapeutics targeting protein dysfunction in genetically defined diseases, today announced the appointment of industry veteran Brad Margus to its board of directors.

“We are excited to welcome Brad to the company during this pivotal time of growth,” said Leslie Williams, co-founder, director and chief executive officer of hC Bioscience. “Brad has successfully established and led multiple life sciences companies, including having recently served as CEO for Cerevance, a clinical-stage company focused on the development of novel treatments for brain diseases. Brad’s deep experience in building companies with novel technologies will be invaluable to hC Bioscience as we develop precision protein editing therapies for patients with cancer and life-limiting genetic
diseases.”

LEARN MORE

Sept 6, 2022

hC Bioscience Expands Leadership and Research & Development Team

hC Bioscience, Inc., a biotech company developing first-in-class tRNA-based therapeutics targeting protein dysfunction in genetically defined diseases and cancer, today announced it has expanded its executive and research & development teams with the additions of Yosef Landesman, Ph.D., as chief scientific officer and Gautam Goel, Ph.D., as chief data science officer.

 

LEARN MORE

FEB 23, 2022

hC Bioscience Announces $24 Million Series A Financing to Develop Innovative Pipeline of Protein-Editing Therapies

hC Bioscience, Inc., a drug discovery and development company focused on first-in-class tRNA-based therapeutics targeting protein dysfunction, has closed a Series A financing of $24 million led by a strong syndicate of investors, including ARCH Venture Partners, Takeda Ventures and 8VC…

 

LEARN MORE

Sept 6, 2022

hC Bioscience Expands Leadership and Research & Development Team

hC Bioscience, Inc., a biotech company developing first-in-class tRNA-based therapeutics targeting protein dysfunction in genetically defined diseases and cancer, today announced it has expanded its executive and research & development teams with the additions of Yosef Landesman, Ph.D., as chief scientific officer and Gautam Goel, Ph.D., as chief data science officer.